Sugi Predict

Sugi Predict / Compounds / SCHEMBL798378

SCHEMBL798378

SCHEMBL798378

CC(=O)CC1(CCCCCCCCCCC2(CC(=O)O)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ CACNA2D1 P54289 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ KMT2A Q03164 1/20 0.34
▸ CYP2C19 P33261 1/20 0.32
▸ OXER1 Q8TDS5 2/20 0.32
▸ SLC15A2 Q16348 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798046 1.00 CYP1A2 (0.38) CYP1A2LMNAUSP2ALDH1A1TSHR
SCHEMBL771865 0.89 CYP1A2 (0.45) CYP1A2LMNAUSP2ALDH1A1TSHR
SCHEMBL771954 0.89 CYP1A2 (0.45) CYP1A2LMNAUSP2ALDH1A1TSHR
SCHEMBL4570512 0.85 CYP1A2 (0.45) CYP1A2LMNAUSP2ALDH1A1TSHR
SCHEMBL23533422 0.84 GPR84 (0.45) ALDH1A1TSHRKMT2AOXER1
SCHEMBL11829345 0.84 GPR84 (0.45) ALDH1A1TSHRKMT2AOXER1
SCHEMBL11838734 0.84 GPR84 (0.45) ALDH1A1TSHRKMT2AOXER1
SCHEMBL798251 0.83 CYP4F2 (0.37) CYP1A2LMNAUSP2ALDH1A1TSHR
SCHEMBL798177 0.83 TBXAS1 (0.38) CYP2C19
SCHEMBL25997302 0.81 OXER1 (0.40) ALDH1A1TSHRKMT2AOXER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364039-A1 Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy UNIV EMORY (US) 2023-11-16 — — US disclosed
US-20140142178-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA KAREUS THERAPEUTICS, SA (CH) 2014-05-22 — — US disclosed
US-20140121267-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA KAREUS THERAPEUTICS, SA (CH) 2014-05-01 — — US disclosed
US-8623897-B2 Methods and compositions for treatment of diabetes and dyslipidemia KAREUS THERAPEUTICS, SA (CH) 2014-01-07 — — US disclosed
US-20120071528-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA KAREUS THERAPEUTICS, SA (CH) 2012-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071528-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA LIPC, PNLIP, LIPA CYP1A2 655/4885LMNA 747/4885USP2 4044/4885
US-20230364039-A1 Methods of Managing Side Effects of a Vasopressin Receptor Antagonist Therapy AVPR2, AVPR1A, AVPR1B CYP1A2 4628/4885LMNA 2139/4885USP2 1640/4885
US-20140121267-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA GPR119, FFAR1, INSR CYP1A2 699/4885LMNA 1950/4885USP2 3644/4885
US-20140142178-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DIABETES AND DYSLIPIDEMIA DHCR7, INSR, GPR119 CYP1A2 659/4885LMNA 2538/4885USP2 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.